Mumbai, Mar 17 (TNT): Lupin Limited on Tuesday said it has entered into a licensing and supply agreement with Zydus Lifesciences Limited to co-market semaglutide injection in India for the treatment of diabetes and related metabolic disorders.
Under the agreement, Lupin will have semi-exclusive rights to co-market Zydus’ semaglutide injection in India under the brand names Semanext and Livarise, while Zydus will continue to market the product under its own brands.
The companies said the partnership aims to expand access to advanced therapies for cardio-metabolic diseases by combining Lupin’s extensive market reach with Zydus’ development capabilities.
As part of the deal, Lupin will pay upfront licensing fees and milestone-based payments to Zydus upon achieving pre-defined targets.
In a releaswe, Lupin Managing Director Nilesh Gupta said the collaboration strengthens the company’s diabetes portfolio and supports its focus on addressing unmet patient needs.
Zydus Managing Director Sharvil Patel said the partnership will help expand access to the therapy, which features a patient-friendly reusable pen device designed to improve ease of use and treatment adherence.
Semaglutide is indicated for adults with inadequately controlled Type 2 Diabetes as well as for chronic weight management in patients with obesity or related conditions, alongside diet and exercise.
TNT KS
Leave a Reply